On the same lines, a recent report showed that inflamed tissues from IBD patients have an elevated NPY immunoreactivity and that pharmacological inhibition of the NPY receptors was able to prevent the release of inflammatory cytokines from IBD patient tissue biopsies, as well as protect against experimental colitis and preserve barrier integrity (78, 100). The gene discussed is NPY; the disease is inflammatory bowel disease.